Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones
Recent appointment of new Chief Financial Officer further strengthens leadership team
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones
Recent appointment of new Chief Financial Officer further strengthens leadership team
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| FRLN | 6.48 | unch | unch |
| Freeline Therapeutics Holdings Plc Adss | |||